Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China.
National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, China.
J Dermatolog Treat. 2024 Dec;35(1):2331782. doi: 10.1080/09546634.2024.2331782. Epub 2024 Mar 21.
Data on the characteristics and treatment outcomes of super-responders and non-super-responders in psoriasis under adalimumab treatment are limited.
A retrospective analysis from psoriatic patients treated with adalimumab was compared to characterize super-responders vs non-super-responders' groups, identify factors associated with super response, and assess treatment outcomes after switching.
15 out of 70 (21.4%) patients were categorized as super-responder. The proportion of patients achieving a PASI 100 response was significantly higher in super-responders than non-super-responders at weeks 12, 24, and 52. Female sex and Charlson Co-morbidity Index were significantly associated with super-responders. A high level of high-density lipoprotein was independently associated with PASI 90 response at weeks 24 and 52. Additionally, nearly 35%-43% of non-super-responders switching to interleukin-17A (IL-17A) inhibitors may achieve a PASI 100 response at week 12. In contrast, all super-responders switching to IL-17A inhibitors achieved a PASI 100 response at week 4.
Super-responders treated with adalimumab have a higher rate of being female and fewer comorbidities. And super-responders have better PASI responses than non-super-responders, whether the patients were treated with adalimumab or switched to IL-17A inhibitors.
阿达木单抗治疗银屑病患者中超级应答者和非超级应答者的特征和治疗结局的数据有限。
对接受阿达木单抗治疗的银屑病患者进行回顾性分析，比较超级应答者和非超级应答者的特征，确定与超级应答相关的因素，并评估转换治疗后的结局。
70 例患者中有 15 例（21.4%）被归类为超级应答者。在第 12、24 和 52 周时，超级应答者中达到 PASI100 应答的患者比例显著高于非超级应答者。女性和 Charlson 合并症指数与超级应答者显著相关。高密度脂蛋白水平较高与第 24 和 52 周时的 PASI90 应答独立相关。此外，约 35%-43%的非超级应答者转换为白细胞介素-17A（IL-17A）抑制剂可能在第 12 周达到 PASI100 应答。相比之下，所有超级应答者转换为 IL-17A 抑制剂在第 4 周时均达到 PASI100 应答。
接受阿达木单抗治疗的超级应答者女性比例更高，合并症更少。并且，无论患者接受阿达木单抗治疗还是转换为 IL-17A 抑制剂，超级应答者的 PASI 应答均优于非超级应答者。
